JonesResearch analyst Soumit Roy upgraded Editas Medicine (EDIT) to Buy from Hold with an $8 price target With Editas nearing IND/CTA submission of their heterozygous familial hypercholesterolemia gene editing therapy, EDIT-401, the firm has added HeFH to its model with a launch year for EDIT-401 in 2031.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EDIT: